BETHESDA, Md., Oct. 31 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammation andautoimmune diseases, today announced that Dr. Christian Itin, President andChief Executive Officer of Micromet, will present at the Acumen BioFin Rodman& Renshaw 9th Annual Healthcare Conference in New York, on Wednesday, November7, 2007 at 9:50am Eastern Time (3:50pm Central European Time).
An audio webcast of Dr. Itin's remarks will be available live andaccessible through Micromet's website at www.micromet-inc.com, as well as areplay and download of the presentation slides following the event.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the developmentof novel, proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Three of its antibodies are in clinical development.MT103 (MEDI-538), the first antibody developed using the BiTE(R) technologyplatform to be clinically validated in Micromet's product pipeline, is beingevaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies thatactivate a patient's own cytotoxic T cells to eliminate cancer cells.Micromet is developing MT103 in collaboration with MedImmune, a subsidiary ofAstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201),a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumabis being developed by Micromet in collaboration with Merck Serono, a divisionof Merck KGaA in Darmstadt, Germany, in a phase 1b clinical trial evaluatingMT201 in combination with docetaxel for the treatment of patients withmetastatic breast cancer. The third clinical stage antibody is MT293(formerly D93); also known as TRC093, a first-in-class humanized monoclonalantibody that inhibits angiogenesis and tumor cell growth by binding cleavedcollagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is beingdeveloped in a phase 1 clinical trial for the treatment of patients withcancer and age-related macular degeneration. In addition, Micromet hasestablished a collaboration with Nycomed for the development andcommercialization of MT203, Micromet's human antibody neutralizing theactivity of GM-CSF, which has potential applications in the treatment ofinflammatory diseases, such as rheumatoid arthritis, as well as autoimmunediseases.
SOURCE Micromet, Inc.